RMD logo

RESMED INC

RMDNYSE
πŸ† #334 by market capEarnings Oct 28US Equity
$379.35β–² $20.11 (+5.30%)
Simulated price
1hβ€”
24hβ–² 5.3%
7dβ€”
14dβ€”
30dβ€”
1yβ€”
🏦Market Cap
$31.92B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+9.8%
Slowing
πŸ“ŠGross Margin
61.1%
High
πŸ’΅FCF Margin
28.8%
Strong
βš–οΈP/S Ratio
5.6x
Fair
Otter Score
60
Fair
No chart data available for RMD.

Trading Snapshot

Day Range
$375.42 – $386.66
52-Week Range
$180.27 – $293.81
Volume
$1.72B
Avg Volume
$2.12B
Shares Outstanding
145.1M
Next Earnings
Oct 26, 2026

Fundamentals Snapshot

Annual Revenue
$5.65B
Last Q Revenue
$1.46B
P/E Ratio
20.9
P/S Ratio
5.6x
EPS (TTM)
$10.44
Dividend Yield
1.10%

Why Investors Own RMD

  • βœ“High-growth profile β€” revenue up +32.9% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 49% gross margin and 6% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$5.65Bβ–² +36.5% YoY
Gross Margin (TTM)
48.9%β–² +2.1% YoY
Operating Income (TTM)
$2.10Bβ–² +36.5% YoY
Free Cash Flow (TTM)
$317Mβ–² +36.5% YoY

About RESMED INC

ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
60/100

Analyst Price Target

β“˜
Average Target
$430.31
β–² +13.4% Upside
High Target$491.68
Low Target$351.86
Based on 35 analysts

Latest News & Updates